QQQ   310.34 (+1.43%)
AAPL   159.28 (+1.19%)
MSFT   273.78 (+0.57%)
META   202.16 (+2.20%)
GOOGL   104.92 (+3.66%)
AMZN   100.61 (+2.97%)
TSLA   197.58 (+7.82%)
NVDA   261.99 (+1.15%)
NIO   9.27 (+5.94%)
BABA   83.70 (+3.33%)
AMD   95.93 (-0.91%)
T   18.54 (+0.27%)
F   11.72 (+4.83%)
MU   58.63 (+1.72%)
CGC   1.97 (+5.91%)
GE   92.18 (+2.51%)
DIS   96.54 (+2.46%)
AMC   4.41 (+3.28%)
PFE   40.66 (-0.37%)
PYPL   76.72 (+4.79%)
NFLX   305.79 (+0.22%)
QQQ   310.34 (+1.43%)
AAPL   159.28 (+1.19%)
MSFT   273.78 (+0.57%)
META   202.16 (+2.20%)
GOOGL   104.92 (+3.66%)
AMZN   100.61 (+2.97%)
TSLA   197.58 (+7.82%)
NVDA   261.99 (+1.15%)
NIO   9.27 (+5.94%)
BABA   83.70 (+3.33%)
AMD   95.93 (-0.91%)
T   18.54 (+0.27%)
F   11.72 (+4.83%)
MU   58.63 (+1.72%)
CGC   1.97 (+5.91%)
GE   92.18 (+2.51%)
DIS   96.54 (+2.46%)
AMC   4.41 (+3.28%)
PFE   40.66 (-0.37%)
PYPL   76.72 (+4.79%)
NFLX   305.79 (+0.22%)
QQQ   310.34 (+1.43%)
AAPL   159.28 (+1.19%)
MSFT   273.78 (+0.57%)
META   202.16 (+2.20%)
GOOGL   104.92 (+3.66%)
AMZN   100.61 (+2.97%)
TSLA   197.58 (+7.82%)
NVDA   261.99 (+1.15%)
NIO   9.27 (+5.94%)
BABA   83.70 (+3.33%)
AMD   95.93 (-0.91%)
T   18.54 (+0.27%)
F   11.72 (+4.83%)
MU   58.63 (+1.72%)
CGC   1.97 (+5.91%)
GE   92.18 (+2.51%)
DIS   96.54 (+2.46%)
AMC   4.41 (+3.28%)
PFE   40.66 (-0.37%)
PYPL   76.72 (+4.79%)
NFLX   305.79 (+0.22%)
QQQ   310.34 (+1.43%)
AAPL   159.28 (+1.19%)
MSFT   273.78 (+0.57%)
META   202.16 (+2.20%)
GOOGL   104.92 (+3.66%)
AMZN   100.61 (+2.97%)
TSLA   197.58 (+7.82%)
NVDA   261.99 (+1.15%)
NIO   9.27 (+5.94%)
BABA   83.70 (+3.33%)
AMD   95.93 (-0.91%)
T   18.54 (+0.27%)
F   11.72 (+4.83%)
MU   58.63 (+1.72%)
CGC   1.97 (+5.91%)
GE   92.18 (+2.51%)
DIS   96.54 (+2.46%)
AMC   4.41 (+3.28%)
PFE   40.66 (-0.37%)
PYPL   76.72 (+4.79%)
NFLX   305.79 (+0.22%)
NASDAQ:OPT

Opthea - OPT Stock Forecast, Price & News

$4.20
-0.18 (-4.11%)
(As of 03/21/2023 12:00 AM ET)
Add
Compare
Today's Range
$4.19
$4.40
50-Day Range
$4.20
$5.67
52-Week Range
$4.19
$8.50
Volume
1,286 shs
Average Volume
2,721 shs
Market Capitalization
$245.28 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.00

Opthea MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
400.0% Upside
$21.00 Price Target
Short Interest
Bearish
0.13% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.48mentions of Opthea in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.14) to ($1.89) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.82 out of 5 stars

Medical Sector

782nd out of 983 stocks

Biological Products, Except Diagnostic Industry

136th out of 163 stocks


OPT stock logo

About Opthea (NASDAQ:OPT) Stock

Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema (DME), as well as a first in class VEGF-C/D inhibitors for treatment with VEGF-A inhibitors to treat wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

Receive OPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Opthea and its competitors with MarketBeat's FREE daily newsletter.

OPT Stock News Headlines

Opthea Stock (NASDAQ:OPT), Dividends
Check Out This 6-Year Win Streak
Despite the volatility of the last few years, this reclusive millionaire hasn’t closed a losing trade since July 2016. He just plugs away, executing what may be the most effective investment strategy on Earth. He turned $50K into $5.3M! Want to see the details? Click HERE to watch it for yourself. pixel
Citigroup Cuts Opthea (NASDAQ:OPT) Price Target to $22.00
Check Out This 6-Year Win Streak
Despite the volatility of the last few years, this reclusive millionaire hasn’t closed a losing trade since July 2016. He just plugs away, executing what may be the most effective investment strategy on Earth. He turned $50K into $5.3M! Want to see the details? Click HERE to watch it for yourself. pixel
Opthea to Present at the FLORetina 2022 Congress
Why the Opthea share price is pushing higher today
Citigroup Maintains Buy Rating for Opthea: Here's What You Need To Know
Opthea To Present at Upcoming Investor Conferences
Opthea receives $4.9M in R&D tax incentive
Opthea Receives A$6.6 m R&D Tax Incentive
See More Headlines
Receive OPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Opthea and its competitors with MarketBeat's FREE daily newsletter.

OPT Company Calendar

Today
3/21/2023
Fiscal Year End
6/30/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OPT
Fax
N/A
Employees
2,021
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$21.00
High Stock Price Forecast
$31.00
Low Stock Price Forecast
$13.00
Forecasted Upside/Downside
+400.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$90,000.00
Book Value
$1.09 per share

Miscellaneous

Free Float
56,526,000
Market Cap
$245.28 million
Optionable
Not Optionable
Beta
0.43

Key Executives

  • Dr. Megan Baldwin M.A.I.C.D. (Age 48)
    MAICD, Ph.D., MD, CEO & Exec. Director
    Comp: $490.24k
  • Ms. Judith J. Robertson B.A. (Age 62)
    M.B.A., Chief Commercial Officer
    Comp: $495.5k
  • Dr. Joel Naor M.D.
    MBA, MSc, Chief Medical Officer
  • Ms. Karen Adams CPA (Age 51)
    VP of Fin. & Company Sec.
    Comp: $260.12k
  • Mr. Timothy E. Morris CPA (Age 61)
    CPA, Chief Financial Officer
  • Ms. Annie Lee
    Fin. & Operations Mang.
  • Dr. Michael Gerometta Ph.D. (Age 58)
    Head of Chemistry, Manufacturing & Controls Devel.
  • Mr. Bruno Gagnon BPHARM
    M.Sc., Sr. VP of Global Clinical Operations
  • Dr. Ian Leitch (Age 59)
    Director of Clinical Research
  • Dr. James Goding
    Independent Consultant













OPT Stock - Frequently Asked Questions

Should I buy or sell Opthea stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Opthea in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OPT shares.
View OPT analyst ratings
or view top-rated stocks.

What is Opthea's stock price forecast for 2023?

4 analysts have issued twelve-month target prices for Opthea's stock. Their OPT share price forecasts range from $13.00 to $31.00. On average, they anticipate the company's share price to reach $21.00 in the next twelve months. This suggests a possible upside of 400.0% from the stock's current price.
View analysts price targets for OPT
or view top-rated stocks among Wall Street analysts.

How have OPT shares performed in 2023?

Opthea's stock was trading at $5.36 at the beginning of the year. Since then, OPT stock has decreased by 21.6% and is now trading at $4.20.
View the best growth stocks for 2023 here
.

When did Opthea IPO?

(OPT) raised $161 million in an initial public offering on Friday, October 16th 2020. The company issued 9,300,000 shares at $17.26 per share. Citigroup and SVB Leerink acted as the underwriters for the IPO and Oppenheimer & Co. and Truist Securities were co-managers.

What is Opthea's stock symbol?

Opthea trades on the NASDAQ under the ticker symbol "OPT."

Who are Opthea's major shareholders?

Opthea's stock is owned by a number of retail and institutional investors. Top institutional investors include Victory Capital Management Inc. (2.02%), Victory Capital Management Inc. (2.02%), Victory Capital Management Inc. (2.02%) and Millennium Management LLC (0.28%).

How do I buy shares of Opthea?

Shares of OPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Opthea's stock price today?

One share of OPT stock can currently be purchased for approximately $4.20.

How much money does Opthea make?

Opthea (NASDAQ:OPT) has a market capitalization of $245.28 million and generates $90,000.00 in revenue each year.

How many employees does Opthea have?

The company employs 2,021 workers across the globe.

How can I contact Opthea?

Opthea's mailing address is LEVEL 4 650 CHAPEL STREET, SOUTH YARRA VICTORIA C3, 3141. The official website for the company is www.opthea.com. The company can be reached via phone at 61-3-9826-0399.

This page (NASDAQ:OPT) was last updated on 3/21/2023 by MarketBeat.com Staff